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Epinephrine and dDAVP administration in patients with congenital
nephrogenic diabetes insipidus. Evidence for a pre.cyclic AMP V2 recep.
tor defective mechanism. We recently showed that the administration of
the antidiuretic V2 specific agonist, 1-desamino[8-D-arginine]vaso-
pressin (dDAVP), to seven male patients with congenital nephrogenic
diabetes insipidus (CNDI) did not cause a decrease in blood pressure
nor an increase in plasma renin activity or factor VILIc or von
Willebrand factor release. In normal subjects, plasma renin activity,
coagulation factors and plasma cyclic AMP are stimulated not only by
dDAVP but also by the administration of epinephrine. In the present
study, we measured tissue plasminogen activator (activity and antige-
nicity), von Willebrand factor multimers, plasma and urinary cyclic
AMP concentrations following dDAVP or epinephrine administration.
We infused epinephrine into three male patients with CNDI. Factor
Vilic and tissue plasminogen activator augmented by 75 to 100% and
von Willebrand Factor multimers were increased; plasma renin activity
and plasma cyclic AMP concentration increased by 200%. None of
these values changed when the same subjects as well as eleven other
male patients with CNDI received dDAVP. Furthermore, dDAVP
administration increased plasma cyclic AMP concentrations in normal
subjects, but not in 14 male patients with CNDI. These results demon-
strate the specificity of the extrarenal V2 receptor defect expressed in
our patients. The lack of a plasma cyclic AMP response to the
administration of dDAVP would suggest an altered pre-cyclic AMP
stimulation mechanism.
The antidiuretic hormone arginine-vasopressin (AVP) inter-
acts with two types of receptors: V1 receptors, which are
present in blood vessels, liver and anterior pituitary, and
mediate the vasopressor, metabolic and adrenocorticotrophic
hormone releasing responses to the administration of AVP; and
V2 receptors, present in the kidney distal nephron, which are
responsible for the antidiuretic response to AVP administration
[1]. V1 receptors are linked to the phosphoinositol second
messenger system, whereas V2 receptors activate adenylate
cyclase [I]. Congenital nephrogenic diabetes insipidus is a rare
Received for publication February 9, 1989
and in revised form May 19, 1989
Accepted for publication May 26, 1989
© 1989 by the International Society of Nephrology
X-linked disorder associated with renal tubular resistance to
AVP [2]. Male patients do not give an antidiuretic response to
the administration of either arginine-vasopressinor the strong
antidiuretic (V2) agonist l-desamino[8-D-arginine]vasopressin
(dDAVP); their renal V2 receptor responses are abnormal.
However, their V1 receptor responses are apparently intact
since the administration of AVP induces skin blanching, ab-
dominal cramps, and the stimulation of the synthesis of pros-
taglandin E2 [3, 4]. We recently showed that in male patients
with congenital nephrogenic diabetes insipidus, blood pressure
did not decrease and that plasma renin activity (PRA) and the
release of the coagulation factors, Factor Vilic (FVIIIc) and
von Willebrand factor (vWF), did not increase in response
to the administration of dDAVP [5]. Hemodynamic responses
to the administration of [4-valine,8-D-argininejvasopressin
(VDAVP), another selective V2 agonist, have been observed in
anephric dogs [6], and an increase in the concentrations of the
coagulation factors has been observed in anephric patients [7].
The lack of hemodynamic and coagulation factor responses to
the administration of dDAVP in patients with congenital neph-
rogenic diabetes insipidus would thus suggest an abnormal
extrarenal V2 receptor response.
The specificity and the mechanism(s) underlying these altered
renal and extrarenal V2 receptor responses are unknown. The
studies presented here were designed to answer the following
questions: 1) are the defective coagulation factor responses
specific for dDAVP administration, that is, could normal coag-
ulation factor responses to the administration of epinephrine be
shown in patients with congenital nephrogenic diabetes insipi-
dus; and 2) are plasma cyclic adenosine monophosphate (cyclic
AMP) measurements a possible indicator of a pre-cyclic AMP
stimulation defect in these patients. If plasma cyclic AMP is
stimulated by epinephrine and by dDAVP in normal subjects
but only by epinephrine in patients with congenital nephrogenic
diabetes insipidus, a defect at a pre-cyclic AMP step is implied.
In our earlier study, we measured the hemodynamic and FVIIIc
and vWF responses to dDAVP administration in a smaller
group of male patients with congenital nephrogenic diabetes
insipidus [5]. In addition, in the present study, we measured
t-PA activity, antigenicity, vWF multimers, plasma and urinary
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cyclic AMP concentrations following dDAVP or epinephrine
administration.
Methods
Study subjects
One of the three groups of subjects we studied consisted of 14
male patients with congenital nephrogenic diabetes insipidus (4
to 45 years old, mean age 23.6 3.0 years). Seven of these
patients have been described in a previous report [5]. Three
new patients belong to the archetype Nova-Scotian "Hope-
well" pedigree [81. All have a documented lifelong history of
polyuria and polydipsia, normal or elevated plasma concentra-
tion of AVP and dilute urine despite the administration of AVP
or dDAVP. The baseline plasma concentration of arginine-
vasopressin in these patients who had free access to water was
4.2 1.0 pg/mI. Plasma arginine-vasopressin was measured by
radioimmunoassay [9].
The second study group consisted of 11 women who were
obligatory carriers of the gene for congenital nephrogenic
diabetes insipidus (25 to 69 years old, mean age 42.7 3.8
years). Six of these women have been described in a previous
report [5]. Three, who were new mothers, belong to the
"Hopewell" pedigree [8]. All these subjects were apparently in
good health with no record of overt polyuria or polydipsia. The
baseline plasma concentration of arginine-vasopressin in these
patients was 1.31 0.32 pg/mI.
The third group contained five normal subjects, one woman
and four men (24 to 30 years old). Three subjects were studied
two times (at least 12 months apart) and a total of eight dDAVP
infusions were performed.
Epinephrine administration: Hemodynamic, coagulation
factor and cyclic AMP measurements
Three brothers (aged 29 to 31 years old) with congenital
nephrogenic diabetes insipidus received an intravenous infusion
of epinephrine (4 to S pg per kg of body wt during 20 to 25 mm).
This dosage has been previously shown to stimulate the release
of FVIIIc and tissue plasminogen activator (t-PA) in normal
subjects [7]. Arterial blood pressure (by sphigmo-manometry)
and pulse rate were recorded every 10 minutes before the
epinephrine infusion, every two minutes during the 20 to 25
minute infusion, every five minutes during 25 to 60 minute
period after the infusion, and every 10 minutes thereafter. The
electrocardiogram was constantly monitored during the test.
The infusion was discontinued when systolic blood pressure
increased to a value higher than 150 mm Hg. The first two
patients studied received 5 tg/kg body wt during 25 minutes;
their systolic blood pressure remained below 145 mm Hg. In the
third patient, twenty minutes after the beginning of the infusion,
systolic blood pressure increased to 152 mm Hg; the epineph-
rime infusion was discontinued and the systolic blood pressure
returned to baseline values within the next three minutes. No
premature ventricular beats occurred in any of the patients.
After a 30-minute equilibration period, two to three baseline
blood samples were obtained (—60, —30, and 0 minutes),
epinephrine was infused from 0 to 20 or 25 minutes and
additional blood samples were obtained at 30, 60, 90 and 120
minutes. Plasma concentrations of FVIIIc, vWF multimers,
t-PA, cyclic AMP, glucose and potassium, and plasma renin
activity were determined. Blood samples were analyzed for
FVIIIc on the day of the test using a one-stage coagulation
assay as previously described [5]. Alternatively, plasma sam-
ples were frozen at —80°C and analyzed later with a chromo-
genic method [10] (Coatest Factor VIII kit, KabiVitrum AB,
Stockholm, Sweden). Samples analyzed by the two methods
gave identical results (FVIIIc [one stage] = 1.039 FVIII [Coa-
test] — 1.672; N = 42, r = 0.89).
The von Willebrand factor multimers were analyzed by
agarose electrophoresis [11] using a 0.75% stacking gel and a
1.5% running gel. Samples were diluted 1:4 in 100mM Tris, 100
mM EDTA, 2% SDS, 8 M urea, 0.005% bromophenol blue (pH
6.8). After heating at 56°C for 15 minutes, 30 d of treated
sample was applied to the electrophoretic gel and left overnight
at 4°C in running buffer solution (50 mrvi Tris, 0.38 M glycine, 1%
SDS, pH 8.35) and a current of 8 to 10 mA. The multimers were
then electroblotted at 100 mA and 4°C as described by Furlong
and Peake [12] using a transfer buffer containing 0.01% SDS
described by Battle et al [13]. The electroblot was washed for
five minutes in Tris buffered saline + Tween 20 (TBST; 10 mrsi
Tris, 150 m NaCI, 0.05% Tween 20) and then blocked with 1%
BSA in TBST for one hour. The membrane was then incubated
in 100 ml of TBST containing 225 jd of rabbit anti-VIII/vWF
(Behring Diagnostics, Marburg, FRG) for 1.5 hours, then rinsed
three times in TBST for five minutes each. The membrane was
then incubated in 75 ml of alkaline phosphatase conjugated,
goat anti-rabbit IgG for 30 minutes, washed three times in TBST
for 10 minutes each and stained with the Protoblot alkaline
phosphatase color development substrates (Promega, Madison,
Wisconsin, USA).
Tissue plasminogen activator antigen was measured in
plasma obtained from citrated blood samples (immediately
centrifuged at 4°C at 9,500 x g and stored at —80°C until
analyzed). These samples were not acidified. An Elisa method,
similar to the Imubind-5 kit (American Diagnostic, Inc., New
York, New York, USA) was used. Miniature polystyrene test
tubes (Immulon 2 Removawell strips, Dynatech Laboratories
Inc., Virginia, USA) were coated with goat anti-t-PA antibodies
obtained from American Diagnostic, Inc. Lyophilized t-PA
(KabiVitrum, Stockholm, Sweden), goat gamma-globulins
(Jackson Immunoresearch Laboratories Inc., West Grove,
Pennsylvania, USA), peroxydase conjugated anti-t-PA IgG
(Biopool AB, Box 1454, S-90124 Umea, Sweden) and orthophe-
nylenediamine (Sigma Chemical Co., Montreal) were also used.
For t-PA activity determinations, the citrated blood samples
were immediately acidified by mixing 1 ml of the blood with 500
d of a 1 M sodium acetate buffer solution pH 3.9 and then
centrifuged at 9,500 x g for four minutes. The acidified plasma
samples were stored at —80°C. The t-PA activity was measured
according to a recently described photometric assay [14, 15]
with the following modifications: the chromogenic substrate
was S-2390 (0.45 M; KabiVitrum) and the plasminogen (0.3
Casein U/mI; Glu-plasminogen, KabiVitrum) was activated by
poly-D-lysine (0.4 ps; ICN, Montreal).
Plasma cyclic AMP was measured using a commercial kit
(cAMP['251] assay system, Amersham, Oakville, Ontario, Can-
ada). Plasma concentrations of epinephrine were measured by a
radioenzymatic assay [16].
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Table 1. Baseline coagulation and biochemical variables in the study groups before dDAVP infusion
Group (no)
Factor VILIc
%
t-PA antigen
ng/ml
t-PA activity
lU/mi
Plasma
cyclic AMP
pmoi/ml
Urinary
cyclic AMP
nmol/min/l.73 m2
Plasma
renin activity
ng/mi/hr
Normal subjects, N = 8 101.3 10.2 3.87 0.95 0.77 0.15 15.96 1.52 2.9 0.6 1.10 0.15
Obligatory carriers, N = 11 125.6 18.0 10.1 2.5a 0.29 0.08a 23.48 2.31a 2.8 1.2 1.98 0.39
Patients with congenital 121.5 18.1 6.74 1.4 0.46 0.13 24.49 l.55a 2.9 0.5 2.68 0.45a
nephrogenic diabetes
insipidus, N = 14
Values are mean SE.
a Significant differences as compared to normal subjects.
dDAVP administration: Hemodynamic, coagulation factor
and cyclic AMP measurements
After an interval of at least two weeks the three patients with
congenital diabetes insipidus received an intravenous adminis-
tration of dDAVP (0.3 pg/kg body wt, up to a maximum dose of
24 g) as previously described [5]. The responses to dDAVP
administration were similar to those obtained in 11 other male
patients with congenital nephrogenic diabetes insipidus. The
results for this entire group of 14 patients as well as the
responses to dDAVP administration in 11 female obligatory
carriers and in 5 normal subjects are presented here. FVIIIc and
plasma renin activity were measured in all the patients. Tissue
plasminogen activator responses to dDAVP administration
were measured in seven male patients with congenital nephro-
genic diabetes insipidus, four obligatory carriers and four
normal subjects. In normal subjects blood for plasma renin
activity determinations was obtained at —30, 0, 10, 20, 30, 60,
90, 120, 150 minutes after dDAVP administration.
Plasma cyclic AMP responses to dDAVP administration and
cyclic AMP excretion rates were measured. Urine was obtained
by spontaneous voiding. One thirty-minute collection was ob-
tained before and three sixty-minute collections were obtained
after dDAVP administration (60, 120, 150 mm).
Statistical analysis
All comparisons were made by analysis of variance [17].
Repeated measurements in the same group of subjects were
compared with baseline values according to the method of
Dunnett [18] and measurements made in different groups of
subjects during the same study period were compared by
Newman-Keuls analysis. A P value less than 0.05 was consid-
ered to be statistically significant. Values reported below refer
to the following periods: —60, —30, 0, baseline period; 0 to 25
minutes, epinephrine or dDAVP infusion period; 30, 60, 90,
120, 150 observation period after epinephrine or dDAVP infu-
sion. Results are reported as the mean SE of either absolute
values or percentages of baseline values.
Protocol approval and consent
All studies were approved by our institutional ethical review
committee. The normal subjects were paid and all participants
in the study gave written informed consent.
Results
Baseline values for coagulation factors, plasma renin activity,
plasma cyclic AMP and urinary cyclic AMP excretion rates are
presented in Table 1. Baseline values for Factor Vilic, t-PA
antigen, t-PA activity and urinary cyclic AMP excretion rates
were similar between normal subjects and patients with con-
genital nephrogenic diabetes insipidus. Plasma cyclic AMP and
plasma renin activity were slightly but significantly higher in
patients with congenital nephrogenic diabetes insipidus. These
differences could be related to the reflex release of renin and
catecholamines secondary to a decrease in extracellular fluid
volume in male patients with congenital nephrogenic diabetes
insipidus. Significant differences in t-PA antigen and activity
and plasma cyclic AMP were also observed in obligatory
carriers compared to normal subjects. We have no explanation
for these differences.
The left side (A) of Figures 1, 3 and 4 relates specifically to
the three patients with congenital nephrogenic diabetes insipi-
dus who received epinephrine. The right side (B) of these
figures describes the results obtained in the three groups of
patients after dDAVP administration.
Epinephrine infusion
The epinephrine infusion significantly increased heart rate (67
5 to 84 6 beats/mm), mean arterial blood pressure (84 3
to 93 5 mm Hg), pulse pressure (40 1 to 95 8 mm Hg).
Plasma potassium decreased (4.0 0.1 to 2.9 0.2 mEq/liter)
and plasma glucose increased (92 2 to 148 11 mg/dl). The
plasma concentration of epinephrine was 1161 292 pglml 10
minutes after the end of the epinephrine infusion.
Epinephrine produced a twofold rise in FVIIIc and t-PA
antigen (Fig. 1), t-PA activity rose by 300% (Fig. 1) and vWF
multimers increased (Fig. 2). Plasma renin activity rose by
130% (Fig. 3) and plasma cyclic AMP by 250% (Fig. 4). The
increases in FVIIIc and t-PA were equal to those previously
reported in normal subjects after epinephrine administration
[7]. Epinephrine is a difficult drug to infuse due to untoward
side-effects, and, since statistically significant results were
obtained with three patients, we decided not to test a larger
number of subjects and to use historical normal controls [7].
dDAVP infusion
In normal subjects, dDAVP administration increased FVIIIc
concentrations by 250%, t-PA antigenicity by 350% and t-PA
activity by 1000% (Fig. 1), vWF multimers were increased (Fig.
2) and plasma renin activity rose twofold (Fig. 3). A significant
inverse correlation (r = —0.76) was calculated between mean
arterial blood pressure and plasma renin activity. Plasma cyclic
AMP concentration increased by 60% (Fig. 4).
These responses were not observed in 14 patients with
congenital nephrogenic diabetes insipidus and variable (usually
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Fig. 1. FVIIIc, t-PA antigen and t-PA activity responses to epinephrine (A) and dDA VP (B) infusions. A. Epinephrine (4 to 5 .&g per kilogram of
body wt) was infused from 0 to 25 minutes into 3 patients with congenital nephrogenic diabetes insipidus (•). B. dDAVP (0.3 sg per kg of body
wt) was infused from 0 to 20 minutes into 14 patients with congenital nephrogenic diabetes insipidus (•), 11 obligatory carriers of the nephrogenic
diabetes insipidus gene (A) and 5 normal subjects (8 studies) (. Asterisks indicate significant differences from baseline values (at —60, —30 and
0 minutes). Error bars are contained within the symbol when not visible.
half) responses were observed in obligatory carriers. Plasma
renin activity and t-PA activity responses were not intermediate
in obligatory carriers. The changes in FVIIIc concentration,
t-PA antigenicity and activity, plasma renin activity and plasma
cyclic AMP concentration in the group with congenital nephro-
genie diabetes insipidus were significantly different from those
in the other two groups.
Urinary cyclic AMP excretion rates were unchanged after
dDAVP administration in normal subjects (baseline: 2.9 0.6
nmollmin/l .73 m; 3 consecutive 60-mm urine collections post-
dDAVP: 2.8 0.3, 2.6 0.5, 3.0 0.7 nmollmin/1.73 m2) and
in patients with congenital nephrogenic diabetes insipidus
(baseline: 2.9 0.5 nmol/min/1 .73 m2; 3 consecutive 60-mm
urine collections post-dDAVP: 4.2 0.6, 3.2 0.5, 4.3 0.6
nmollminhl .73 ma). Significant positive correlations were calcu-
lated in normal individuals between urinary cyclic AMP and
urinary creatinine concentrations (r = 0.94) and between un-
nary cyclic AMP concentrations and urinary osmolality (r =
0.89).
Discussion
This study shows that in patients with congenital nephrogenic
diabetes insipidus receiving epinephrine the concentrations of
the coagulation factors increased to equal those previously
reported in normal subjects after epinephrine administration
[7]. In this regard, Mannucci et al [7] demonstrated an 80%
increase in Factor Vilic and plasminogen activator after a 6
pg/kg epinephrine infusion in six normal subjects. Similar
increases were obtained in our three patients with congenital
nephrogenic diabetes insipidus (Fig. 1). In contrast, there were
no increases in the concentrations of the coagulation factors in
response to dDAVP administration in either the same subjects
or the 14 male patients with congenital nephrogenic diabetes
insipidus. In an earlier study, we measured FVIIIc and vWF
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Fig. 2. NaDodSO4-agarose elect rophoresis of plasma von Willebrand factor in normal subjects and patients with congenital nephrogenic diabetes
insipidus. dDAVP induced multimers (indicated by a parenthesis) in normal subjects but not in patients with congenital nephrogenic diabetes
insipidus who however had an increase of multimers after epinephrine administration. dDAVP also induced the formation of doublet-like structures
(arrows). Similar structures were also observed after epinephrine administration in patients with congenital nephrogenic diabetes insipidus. Plasma
samples were applied at the top of the gel (arrow at the top of each figure).
responses to dDAVP administration in a smaller group of seven
male patients with congenital nephrogenic diabetes insipidus
[5]. In addition, in the present study we measured t-PA activity,
antigenicity, vWF multimers, plasma and urinary cyclic AMP
concentrations following dDAVP or epinephrine administra-
tion.
In 1961, Ingram discovered that the injection of epinephrine
into healthy volunteers was followed by a short-term rise in the
coagulant activity of Factor VIII [9]. Subsequently, Mannucci
et al reported a transient increase in t-PA following a 6 pg/kg
epinephrine infusion in normal subjects [7]. Tissue plasminogen
activator, a serine proteinase with high specificity for plasmin-
ogen, is also released after dDAVP administration. The magni-
tude of the t-PA response to dDAVP administration usually
correlates with those of FVIIIc and vWF in normal subjects
[20]. The release of t-PA following dDAVP administration is not
accompanied by signs of systemic activation of the fibrinolytic
system or hyperplasminemia. Therefore, the release is most
probably secondary to a marked decrease in the plasma con-
centrations of the naturally occurring, fast acting inhibitor of
t-PA [21]. The administration of dDAVP also induces the
appearance in plasma of larger than normal vWF multimers
which could be associated with the shortening of the bleeding
time observed after dDAVP administration [21]. The mecha-
nisms by which the administration of epinephrine or dDAVP
release these coagulation factors from the vascular endothelium
are not well understood, but specific receptor-mediated re-
sponses seem to be involved. The t-PA and FVIIIc responses to
epinephrine administration were diminished or abolished by
propranolol pre-treatment [22, 23], an observation in favor of a
beta-receptor-mediated response. Also the coagulation re-
sponses observed after dDAVP were not modified by propran-
olol, aspirin or naloxone, suggesting that beta-adrenergic mech-
anisms, prostaglandins and beta endorphins mediators were
likely not involved [24, 25].
Male patients with congenital nephrogenic diabetes insipidus,
that is, with malfunctioning renal V2-receptor responses, give
no coagulation responses to dDAVP administration [5, 26, 271.
Since in the same patients, the responses to epinephrine are not
impaired, a V2 specific receptor-mediated defect is implied.
Endothelial vascular cells could bear these putative V2 recep-
tors. Alternatively dDAVP, through a V2 receptor mechanism,
may stimulate the release of an unknown mediator acting on the
release of FVIIIc, vWF and t-PA. These extrarenal V2 receptor
mechanisms are defective in patients with congenital nephro-
genic diabetes insipidus.
Plasma renin activity was stimulated by epinephrine but not
by dDAVP administration in patients with congenital nephro-
genic diabetes insipidus. In normal subjects, mean arterial
pressure decreased after dDAVP administration and an inverse
correlation was observed between mean arterial blood pressure
and plasma renin activity. It is unlikely that the renin release
observed after dDAVP in normal individuals might be mediated
by a reflex release of catecholamines (secondary to a decrease
in mean arterial blood pressure) since Schwartz et al demon-
strated that [4-valine,8-D-arginine]vasopressin (VDAVP), an-
other selective V2 agonist decreased mean arterial blood pres-
sure and stimulated plasma renin activity after propranolol
administration [28]. The beta-adrenergic stimulation of juxta-
glomerular cells is thus unlikely to account for the renin-
stimulating properties of dDAVP. An alpha-adrenergic renin-
stimulating mechanism is also unlikely since: 1) a decrease in
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Fig. 3. Plasma renin activity responses to epinephrine and to dDA VP. A. Epinephrine (4 to 5 g per kg of body wt) was infused from 0 to 25
minutes into 3 patients with congenital nephrogenic diabetes insipidus (•). B. dDAVP (0.3 g per kg of body wt) was infused from 0 to 20 minutes
into 14 patients with congenital nephrogenic diabetes insipidus (•), 11 obligatory carriers of the nephrogenic diabetes insipidus gene (A) and 5
normal subjects (8 studies) ). Asterisks indicate significant difference from baseline values (at —60. —30 and 0 minutes).
Time, minutes
Fig. 4. Plasma cyclic AMP responses to epinephrine and to dDA VP. A. Epinephrine (4 to5 tgper kg of body wt) was infused from 0 to 25 minutes
into 3 patients with congenital nephrogenic diabetes insipidus (. B. dDAVP (0.3 sg per kg of body wt) was infused from 0 to 20 minutes into
14 patients with congenital nephrogenic diabetes insipidus (•). 11 obligatory carriers of the nephrogenic diabetes insipidus gene (A) and 5 normal
subjects (8 studies) (s). Asterisks indicate significant differences from baseline values (at —60, —30 and 0 minutes).
systemic vascular resistance was observed after dDAVP or
VDAVP [281; and 2) renal blood flow (measured with radioac-
tive microspheres) did not change after VDAVP administration
[6].
Mean arterial blood pressure did not change after dDAVP
administration in patients with congenital nephrogenic diabetes
insipidus and plasma renin activity remained stable. However,
epinephrine administration stimulated plasma renin activity.
The stimulating effect of epinephrine administration is likely
secondary to the hemodynamic effects and to the direct action
on the juxtaglomerular cells. This stimulation of renin activity
also favors a V2-receptor specific defect in patients with con-
genital nephrogenic diabetes insipidus. We did not observe a
stimulation of plasma renin activity after dDAVP administra-
tion in 11 female obligatory carriers of the gene for nephrogenic
diabetes insipidus. The random inactivation of the X chromo-
some bearing the defective gene would predict a variability in
the renin responses to dDAVP administration in these patients.
In a large number of patients, half the normal response should
be obtained. Plasma levels of AVP were within the normal
range (1.31 0.32 pg/ml) in our 11 obligatory carrier patients
and were not in favor of a receptor desensitization mechanism
[5]. We are unable to explain the complete absence of plasma
renin activity stimulation in the obligatory carriers.
The antidiuretic action of vasopressin is mediated by the
sequential steps of vasopressin binding to its cell surface
receptor followed by the receptor mediated stimulation of
adenylate cyclase. Guanine nucleotide binding proteins also
intervene in the transduction process [29]. It is not known
which part of the transduction process is deficient in patients
with congenital nephrogenic diabetes insipidus. Mice with
congenital nephrogenic diabetes insipidus have a defect in renal
medullary cyclic AMP catabolism [30, 31]. However, this
defect is probably not present in humans with congenital
nephrogenic diabetes insipidus, since in humans the disease is
an X-linked inheritance rather than a non-X-linked trait as in
mice [32]. Uttley, Atkinson and Adams assessed urinary excre-
tion of cyclic AMP in response to Pitressin (vasopressin)
administration in three patients with congenital nephrogenic
diabetes insipidus, four carriers and seven controls [33]. They
found no significant difference in cyclic AMP excretion between
the three groups nor any significant increase in urinary excre-
tion after stimulation by Pitressin administration. They found a
close correlation between urinary cyclic AMP excretion and
both urinary concentration and urinary creatinine excretion,
suggesting that the bulk of the cyclic AMP in the urine derives
from glomerular filtration both in the waterloaded and in the
urinary concentrated states [33]. In contrast, cyclic AMP un-
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nary excretion rate increased 10- to 30-fold following stimula-
tion by the administration of parathyroid hormone. This finding
proved to be a useful diagnostic test for pseudohypoparathy-
roidism [34]. Parathyroid hormone administration normally
stimulates urinary cyclic AMP excretion in patients with con-
genital nephrogenic diabetes insipidus, ruling out a guanine-
nucleotide-binding stimulatory protein deficient mechanism
[35]. We are not aware of previous reports of plasma cyclic
AMP measurements after dDAVP administration in patients
with congenital nephrogenic diabetes insipidus.
In our studies, urinary cyclic AMP excretion rates were
unchanged after dDAVP administration in normal subjects and
in our patients with congenital nephrogenic diabetes insipidus.
We thus confirmed that measurements of urinary cyclic AMP
are of no value in differentiating between normal individuals
and our patients resistant to AVP and, like Uttley et al [33], we
found a close correlation betwen urinary cyclic AMP and both
urinary concentration and urinary creatinine. In contrast, in
normal subjects, plasma cyclic AMP concentrations signifi-
cantly increased after dDAVP administration, but no response
was observed in patients with congenital nephrogenic diabetes
insipidus and a minimal response was measured in obligatory
carriers. The increased plasma concentration of cyclic AMP
observed after dDAVP administration was not secondary to the
reflex release of epinephrine since epinephrine plasma concen-
trations were unchanged after dDAVP administration in normal
subjects [36]. The defective plasma cyclic AMP response to
dDAVP administration observed in patients with congenital
nephrogenic diabetes insipidus was specific, since plasma cyclic
AMP concentration increased after epinephrine administration
in these patients. Our results thus suggest that a precyclic AMP
stimulation mechanism is defective in patients with congenital
nephrogenic diabetes insipidus. Providing that the guanine-
nucleotide-binding protein step is normal [35], the defective
gene in the patients we studied with congenital nephrogenic
diabetes insipidus is likely to code for a defective V2 receptor.
In summary, patients with congenital nephrogenic diabetes
insipidus have a selective defect in the V2-mediated stimulation
of the release of the coagulation factors, since the release of
these factors is normally stimulated by the administration of
epinephrine. The administration of dDAVP, a selective V2
agonist, stimulated plasma cyclic-AMP release in normal sub-
jects, but not in our patients with congenital nephrogenic
diabetes insipidus and minimal responses were obtained in
obligatory carriers. These results favor a pre-cyclic-AMP-
altered stimulation mechanism in our patients with congenital
nephrogenic diabetes insipidus.
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